There is a good deal of biomedical research that does not produce scientifically useful data because it fails to recruit a sufficient number of subjects. This fact is typically not disclosed to prospective subjects. In general, the guidance about consent concerns the information required to make intelligent self-interested decisions and ignores some of the information required for intelligent altruistic decisions. Bioethics has worried about the ‘therapeutic misconception’, but has ignored the ‘completion misconception’. This article argues that, other things being equal, prospective subjects should be informed about the possibility of non-completion as part of the standard consent process if (1) it is or should be anticipatable that there is a non-trivial possibility of non-completion and (2) that information is likely to be relevant to a prospective subject's decision to consent. The article then considers several objections to the argument, including the objection that disclosing non-completion information would make recruitment even more difficult.
- Informed Consent
- Research Ethics
- Clinical Ethics
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Read the full text or download the PDF:
Other content recommended for you
- Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis
- Systematic review and metasummary of attitudes toward research in emergency medical conditions
- Assessing research risks systematically: the net risks test
- Phase 1 oncology trials and informed consent
- Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?
- CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
- Participants’ responsibilities in clinical research
- Risk factors associated with Richter’s transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population-based cohort study
- Phase I oncology trials: why the therapeutic misconception will not go away
- Therapeutic appropriation: a new concept in the ethics of clinical research